JP2009535309A5 - 医薬製剤の生産方法およびその方法により生産される医薬製剤 - Google Patents
医薬製剤の生産方法およびその方法により生産される医薬製剤 Download PDFInfo
- Publication number
- JP2009535309A5 JP2009535309A5 JP2009506914A JP2009506914A JP2009535309A5 JP 2009535309 A5 JP2009535309 A5 JP 2009535309A5 JP 2009506914 A JP2009506914 A JP 2009506914A JP 2009506914 A JP2009506914 A JP 2009506914A JP 2009535309 A5 JP2009535309 A5 JP 2009535309A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- producing
- pharmaceutically
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 7
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 4
- 210000000056 organs Anatomy 0.000 claims 3
- DOKOVZHOVUEIBQ-UHFFFAOYSA-N 12-(1H-imidazol-2-yl)dodecan-1-ol Chemical compound OCCCCCCCCCCCCC1=NC=CN1 DOKOVZHOVUEIBQ-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010070863 Toxicity to various agents Diseases 0.000 claims 1
- 201000001203 Wilson disease Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 239000004029 environmental poison Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000002588 toxic Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 231100000224 toxic side effect Toxicity 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
Claims (6)
- １２−イミダゾリル−１−ドデカノールからなる化合物、または薬学的に条件を満たす前記化合物の塩を用いることを特徴とする医薬製剤の生産方法。
- 腫瘍性疾患、アルコール摂取の濫用による病理学的作用、ウイルス性肝炎、脂肪肝、急性および慢性の膵炎、中毒性腎疾患、真性糖尿病の場合の肝臓の抗インシュリン作用、ウィルソン病およびジデローシスの場合の肝臓損傷、もしくは虚血性再灌流による疾患の予防ないし治療のため、環境毒および薬物中毒に対する解毒のため、投薬薬剤の臓器内在期間延長、または化学療法投薬時の有毒副作用克服のために用いられる、請求項１に記載される医薬製剤の生産方法により生産される医薬製剤。
- 脂肪過多症の治療のために用いられる、請求項２に記載の医薬製剤。
- 臓器移植時の再灌注損傷の防止のために、臓器保管前と保管中および被移植者への移植の直前に投与される、請求項２に記載の医薬製剤。
- １２−イミダゾリル−１−ドデカノールからなる化合物、または薬学的に条件を満たす前記化合物の塩を、薬学的に条件を満たす媒体中に含む、請求項２〜４のいずれかに記載の医薬製剤。
- リポソームに包まれている、請求項２〜５のいずれかに記載の医薬製剤。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006019906A DE102006019906A1 (de) | 2006-04-28 | 2006-04-28 | Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptable Salze zur Herstellung einer pharmazeutischen Zubereitung |
| PCT/DE2007/000768 WO2007124734A2 (de) | 2006-04-28 | 2007-04-27 | Verbindungen a-r-x zur herstellung von pharmazeutischen zubereitungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535309A JP2009535309A (ja) | 2009-10-01 |
| JP2009535309A5 true JP2009535309A5 (ja) | 2010-07-15 |
Family
ID=38462536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506914A Pending JP2009535309A (ja) | 2006-04-28 | 2007-04-27 | 化学式ａ−ｒ−ｘの化合物、または薬学的に条件を満たす該化合物の塩を医療製剤の生産に使用する用法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8153676B2 (ja) |
| EP (1) | EP2023911B1 (ja) |
| JP (1) | JP2009535309A (ja) |
| KR (1) | KR101113436B1 (ja) |
| CN (1) | CN101478960B (ja) |
| AU (1) | AU2007246023B2 (ja) |
| BR (1) | BRPI0710796A2 (ja) |
| CA (1) | CA2650577C (ja) |
| DE (2) | DE102006019906A1 (ja) |
| HK (1) | HK1134902A1 (ja) |
| IL (1) | IL194961A0 (ja) |
| MX (1) | MX2008013829A (ja) |
| RU (3) | RU2477275C1 (ja) |
| UA (1) | UA93709C2 (ja) |
| WO (1) | WO2007124734A2 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007051339A1 (de) | 2007-10-26 | 2009-04-30 | Müller-Enoch, Dieter, Prof. Dr. | Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien |
| DE102010012233A1 (de) | 2010-03-19 | 2011-09-22 | Acrovis Biostructures Gmbh | Imidazole |
| DE102010012234A1 (de) | 2010-03-19 | 2011-09-22 | Acrovis Biostructures Gmbh | Pharmazeutisches Kombinationspräparat |
| DE102010012226A1 (de) | 2010-03-19 | 2011-09-22 | Acrovis Biostructures Gmbh | Pharmazeutisches Kombinationspräparat |
| DE102010012224A1 (de) | 2010-03-19 | 2011-09-22 | Acrovis Biostructures Gmbh | Pharmazeutisches Präparat |
| DE102010012232A1 (de) | 2010-03-19 | 2011-09-22 | Acrovis Biostructures Gmbh | Irnidazole |
| DE102010012225A1 (de) | 2010-03-19 | 2011-09-22 | Acrovis Biostructures Gmbh | Kosmetikum |
| DE102010012235A1 (de) | 2010-03-19 | 2011-09-22 | Acrovis Biostructures Gmbh | Imidazole |
| DE102010012223A1 (de) | 2010-03-19 | 2011-09-22 | Acrovis Biostructures Gmbh | Pharmazeutisches Präparat |
| BR112013033309B1 (pt) | 2011-06-24 | 2022-07-05 | Gri Bio, Inc | Uso de tazaroteno e método in vitro para inibição de ativação de células nkt tipo i |
| DE102011112103A1 (de) | 2011-09-02 | 2013-03-07 | Acrovis Biostructures Gmbh | Pharmazeutisches Präparat |
| DE102012018052A1 (de) | 2011-09-21 | 2013-03-21 | Acrovis Biostructures Gmbh | Pharmazeutisches Kombinationspräparat |
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| CN105541727B (zh) * | 2016-01-15 | 2018-01-30 | 徐州医学院 | 一种具放疗增敏功能的脂质分子、其制备方法及其在肿瘤放射治疗药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2016452B (en) | 1978-02-18 | 1982-07-21 | Kissei Pharmaceutical | Imidazole compounds |
| JPS591415A (ja) * | 1982-06-28 | 1984-01-06 | Mochida Pharmaceut Co Ltd | 循環系疾患治療剤 |
| GB2229719B (en) * | 1989-03-30 | 1992-04-29 | Farmos Oy | Novel aromatase inhibiting 4(5)-imidazoles |
| EP0567653A4 (en) * | 1991-11-14 | 1994-06-01 | Sagami Chem Res | Drug for hepatic diseases |
| US20020183333A1 (en) * | 2000-03-29 | 2002-12-05 | Shah Sudhir V. | Compositions and methods for chemotherapy having reduced nephrotoxicity |
| DE102004052697A1 (de) * | 2004-10-29 | 2006-05-04 | Haehner, Thomas, Dr. | Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation |
-
2006
- 2006-04-28 DE DE102006019906A patent/DE102006019906A1/de not_active Withdrawn
-
2007
- 2007-04-27 AU AU2007246023A patent/AU2007246023B2/en not_active Ceased
- 2007-04-27 MX MX2008013829A patent/MX2008013829A/es active IP Right Grant
- 2007-04-27 WO PCT/DE2007/000768 patent/WO2007124734A2/de active Application Filing
- 2007-04-27 RU RU2011150049/04A patent/RU2477275C1/ru not_active IP Right Cessation
- 2007-04-27 BR BRPI0710796-0A patent/BRPI0710796A2/pt not_active IP Right Cessation
- 2007-04-27 US US12/298,179 patent/US8153676B2/en not_active Expired - Fee Related
- 2007-04-27 DE DE112007001669T patent/DE112007001669A5/de not_active Withdrawn
- 2007-04-27 KR KR1020087029198A patent/KR101113436B1/ko not_active IP Right Cessation
- 2007-04-27 CN CN2007800237301A patent/CN101478960B/zh not_active Expired - Fee Related
- 2007-04-27 CA CA2650577A patent/CA2650577C/en not_active Expired - Fee Related
- 2007-04-27 UA UAA200812523A patent/UA93709C2/ru unknown
- 2007-04-27 EP EP07722325.3A patent/EP2023911B1/de active Active
- 2007-04-27 RU RU2008146974/15A patent/RU2446801C2/ru not_active IP Right Cessation
- 2007-04-27 JP JP2009506914A patent/JP2009535309A/ja active Pending
-
2008
- 2008-10-28 IL IL194961A patent/IL194961A0/en unknown
-
2009
- 2009-04-09 RU RU2009113390/15A patent/RU2009113390A/ru unknown
- 2009-12-18 HK HK09111940.9A patent/HK1134902A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535309A5 (ja) | 医薬製剤の生産方法およびその方法により生産される医薬製剤 | |
| JP2009500443A5 (ja) | ||
| RU2470016C2 (ru) | Производное бипиразола | |
| JP2010535814A5 (ja) | ||
| JP2010520200A5 (ja) | ||
| JP2009522376A5 (ja) | ||
| RU2008146974A (ru) | Применение соединений фолмулы а-r-x или их фармацевтически приемлемых солей для получения фармацевтической композиции | |
| JP2010529118A5 (ja) | ||
| JP2007527914A5 (ja) | ||
| JP2006526626A5 (ja) | ||
| WO2009134057A3 (ko) | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 | |
| JP2013509411A5 (ja) | ||
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2005343897A5 (ja) | ||
| JP2008505857A5 (ja) | ||
| JP2006523216A5 (ja) | ||
| JP2007515469A5 (ja) | ||
| AR054238A1 (es) | Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona | |
| JP2012502037A5 (ja) | ||
| JP2010523476A5 (ja) | ||
| CN102573463A (zh) | N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法 | |
| JP2013542955A5 (ja) | ||
| WO2011149250A3 (ko) | 트리카르보닐 테크네슘-99ｍ 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 | |
| JP2008540603A5 (ja) | ||
| JP2007519701A5 (ja) |